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Attenuation of Pressor Responses to Norepinephrine
and Pitressin and Potentiation of Pressor Response
to Angiotensin II by Captopril in Human Subjects
YUTAKA IMAI, M.D., KEISHI A B E , M.D., MASAHIDE SEINO, M.D.,
TOSHIAKI HARUYAMA, M.D., JIRO TAJIMA, M.D., MAKITO SATO, M.D.,
TOSHIKAZU GOTO, M.D., M A S A O HIWATARI, M.D., YUTAKA KASAI, M.D.,
KAORU YOSHINAGA, M.D., AND HIROSHI SEKINO, M.D.
SUMMARY The present study was conducted to investigate the influence of captopril on cardiohemo-
dynamic responses in 38 normal volunteers (20- to 35-year-old men) to exogenously administered vasopressor
substances. Norepinephrine (NE), 0.05, 0.1, and 0.2
 Mg/kg min1; angiotensin II (AH), 5, 10, and 20 ng/kg
min'1; and pitressin (2 mU/kg min'1) were infused for 10 minutes. Each infusion was repeated twice, and the
responses were reproducible. Captopril (50 mg by mouth) significantly attenuated the pressor responses to NE
and pitressin, but the decrease in heart rate in response to NE and pitressin was almost the same before and
after captopril treatment, suggesting that captopril potentiates reflex slowing of the heart. Captopril
significantly potentiated the pressor response to AIL Attenuation of pressor response and potentiation of reflex
slowing of the heart, in response to NE and pitressin, disappeared when a subdepressor dose of AH (1 ng/kg
min'1) was infused in addition to captopril. Infusion of a subdepressor dose of bradykinin (BK), 0.1 fig/kg
min'1, had no influence on the pressor response to NE. In the subjects treated with indomethacin (225 mg/54
hrs), captopril still attenuated the pressor response to NE. These results suggest that captopril attenuates the
pressor responses to NE and pitressin primarily by depletion of endogenous AH; decreased AH may desen-
sitize the contraction of arterial smooth muscle and may potentiate the compensatory reflex mechanism.
(Hypertension 4: 444-451, 1982)
KEY WORDS • blood pressure • heart rate • bradykinin • angiotensin •
indomethacin • vascular reactivity • baroreflex •
plasma renin activity
CAPTOPRIL (SQ 14,225), an orally activeangiotensin-converting enzyme inhibitor,has been shown to be effective in lowering
the blood pressure of hypertensive patients.1-2 It is
generally assumed that the hypotensive effect of cap-
topril may be due to either suppression of angiotensin
II (All) formation or potentiation of bradykinin
(BK), or a combination of both,24 since angiotensin
converting enzyme is identical to kininase II.5 How-
ever, the precise role of the renin-angiotensin and the
kallikrein-kinin systems in mediating the hypotensive
effect of captopril still remains to be determined.
There is documented evidence that captopril lowers
From the Second Department of Internal Medicine, Tohoku
University School of Medicine and Sendai Insurance Hospital, Sen-
dai, Japan.
Supported in part by a research grant for cardiovascular disease
(Grant 54-A-2) from the Ministry of Health and Welfare, Japan.
Address for reprints: Yutaka Imai, M.D., Monash University
Department of Medicine, Prince Henry's Hospital, St. Kilda Road,
Melbourne, Victoria 3004, Australia.
Received May 4, 1981; revision accepted December 4, 1981.
blood pressure in some patients with low renin hyper-
tension2- '•7 and in some anephric patients.8 Ad-
ditional studies are needed to uncover the mechanism
of action of this important therapeutic agent. Okuno
et al.9 recently reported that captopril attenuated the
contractile response to norepinephrine (NE) in the rat
mesenteric artery. In view of these reports, we put
forward a hypothesis that the hypotensive action of
captopril is due to a change in vascular reactivity to
vasopressor substances and modulation of the baro-
reflex mechanism. To test this hypothesis, we ex-
amined the effect of captopril on cardiohemodynamic
responses to several vasoactive substances in normal
volunteers.
Materials and Methods
The present study was conducted on 38 male
volunteers from 20 to 35 years of age, who were nor-
motensive without any known renal or cardiovascular
disease. They gave informed consent before the study.
444
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All subjects were allowed an unrestricted diet (includ-
ing sodium intake), and underwent the studies either
in the morning or the afternoon after a light breakfast
or lunch. Each subject was investigated in the recum-
bent position; blood pressure was measured with an
automatic blood pressure recorder (Roche, Ar-
teriosonde Type 1210) and heart rate by a cardio-
tachometer, at 1-minute intervals throughout the
study. Blood pressure and heart rate of all the subjects
became stable during 1 hour of bedrest in the recum-
bent position. An intravenous infusion of isotonic
glucose solution was started via an indwelling venous
cannula at a rate of 1 ml/min and continued until the
end of the study. Without disturbing the subjects, the
drug solution was then infused by constant infusion
pump (ATOM, Type 201) superimposed on the
glucose infusion.
Drugs used in this study were NE (Noradrenalin,
Sankyo), All (Hypertensin, Ciba), pitressin (Parke-
Davis), BK (BSR 640, Sandoz), captopril (Squibb-
Sankyo), and indomethacin (Inteban SP, Sumitomo).
We had previously determined that 1 /xU of pitressin
(Parke-Davis) was equivalent to 2.5 to 2.7 pg of syn-
thesized arginine vasopressin (unpublished data).
The term "basal" used in the present study refers to
a value obtained just prior to the administration of
vasopressor substances (average of five readings). The
term "control" used in the present study refers to
responses to vasoactive substances before captopril
treatment or BK infusion. The response was defined as
the difference between the "basal value" and the
average of five readings for each dose of vasoactive
substance given. In the cases of NE and All, the final
five readings were averaged, while in the case of pitres-
sin, the five readings from the 3rd to 7th minute in the
course of a 10-minute infusion were averaged, since
tachyphylaxis easily occurred during the infusion of
pitressin. Blood samples for the measurement of
plasma renin activity (PRA) were taken just prior to
the infusion of vasopressor substances with and with-
out captopril treatment; PRA was measured radio-
immunologically as described previously.10
Study Groups
Ten groups for 10 different studies were designed.
One-half of the subjects were studied twice in different
study protocols. The second study was performed at
least 1 week after the first one. In all groups except
Groups 3, 6, and 9, the changes in heart rate in
response to vasopressor substances were expressed as
the value obtained with the highest dose.
Reproducibility of Cardiohemodynamic Responses to
Norepinephrine (Group I), Angiotensin II (Group 2),
and Pitressin (Group 3)
Norepinephrine in doses of 0.05, 0.1, and 0.2 /tg/kg
min"1; All in doses of 5, 10, and 20 ng/kg min1; and
pitressin in a dose of 2 mU/kg min"1 were infused into
three different groups (Groups 1, 2, and 3, each with
five subjects). These infusions were repeated two times
to determine the reproducibility of the responses to
these vasoactive substances. Norepinephrine, All, and
pitressin solutions were diluted to concentrations of 50
Mg/ml, 5 fig/ml, and 0.5 U/ml, respectively, using
physiological saline. At least 1 hour was allowed to
elapse between the first and the second infusion. Three
doses of NE or All were infused for 10 minutes each.
The effects of pitressin were studied using only one
dose, since tachyphylaxis and urge for defecation oc-
curred.
Effect of Captopril on the Cardiohemodynamic
Responses to Norepinephrine (Group 4), Angiotensin
II (Group 5), and Pitressin (Group 6)
Seven (Group 4), six (Group 5), and five (Group 6)
normal volunteers were examined to determine the
effect of captopril on the responses to vasopressor sub-
stances. A control response to the vasopressor sub-
stances was first obtained, and 1 hour later captopril
in a dose of 50 mg was administered orally. One hour
later, the vasopressor substances were infused again.
Doses of the drugs were the same as in Groups 1, 2,
and 3.
Effect of Combined Treatment with Captopril and a
Subdepressor Dose of Angiotensin II on the
Cardiohemodynamic Responses to Norepinephrine
(Group 7) and Pitressin (Group 8)
Five normal volunteers were examined in Groups 7
and 8. The subdepressor dose of All was determined
by extrapolation of the dose-response curve obtained
in Group 2. One hour after obtaining the control pres-
sor responses to NE and pitressin, infusion of All at a
rate of 1 ng/kg min"1 was started in addition to the
oral administration of captopril in a dose of 50 mg.
The second responses to NE and pitressin were tested
during the infusion of All at a low rate. Doses of the
drugs were the same as in Groups 1 and 3.
Effect of Infusion of Subdepressor Dose of Bradykinin
on the Cardiohemodynamic Responses to
Norepinephrine (Group 9)
Five normal volunteers were examined in Group 9.
The responses to NE were examined with only one
dose (0.1 Mg/kg min"1 for 10 minutes). One hour after
the control responses to NE were obtained, BK was
infused in a dose of 0.1 Mg/kg min1 for 20 minutes;
the BK solution was diluted to a concentration of 50
jig/ml using physiological saline. Ten minutes after
the start of BK infusion, NE in a dose of 0.1 Mg/kg
min"1 was infused.
Effect of Combined Treatment with Indomethacin
and Captopril on the Cardiohemodynamic Responses
to Norepinephrine (Group 10)
Five normal volunteers were examined in Group 10.
Indomethacin in a dose of 25 mg was administered
orally every 6 hours for 54 hours; then, 1 hour after
the final administration, the control responses to NE
were examined. One hour later, captopril in a dose of
50 mg was administered orally. After another hour,
the responses to NE were examined again to deter-
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mine the effect of the combined treatment with indo-
methacin and captopril on the responses to NE.
Calculation and Analytical Methods
The mean arterial blood pressure (MAP) was
calculated from systolic and diastolic blood pressure
in the conventional way. The values in the text, table,
and figures are means ± SEM. The dose response
curves for NE and All within a group and those
between groups were analyzed by one-way analysis of
covariance. It was determined whether the slopes of
the linear regression and the corrected means for a few
groups of data on pressor response to vasopressor sub-
stance were different from each other." The pressor
responses to pitressin within a group were analyzed by
Student's t test for paired comparison, and those
between groups were analyzed by analysis of variance.
Results
Table 1 shows the basal MAP and heart rate before
and after captopril or BK administration. In all stud-
ies, no statistically significant difference was found
between the MAP before and after captopril or BK
administration.
Pressor Responses to Norepinephrine, Angiotensin II, and
Pitressin
Figure 1 (upper) shows changes in MAP produced
by NE infusion in 17 subjects before captopril.
Arterial pressure was increased by NE with time and
with doses. Figure 1 (center) shows similar changes in
MAP produced by infusion of All in 11 normal sub-
jects. With infusion of pitressin (fig. 1 lower), MAP in-
creased rather rapidly and attained a peak 4 minutes
after the start of infusion, but failed to remain ele-
vated and returned toward preinfusion level.
Reproducibility of the Cardiohemodynamic Responses to
Norepinephrine, Angiotensin II, and Pitressin (Groups 1, 2,
and 3)
As shown in figures 2 left, 3 left, and 4 left, the
pressor response to each dose of vasopressor' sub-
stances obtained from the first administration was not
significantly different from that obtained from the
second administration. The pressor responses to NE,
All , and pitressin were reproducible. The reflex slow-
ing of the heart in response to NE and pitressin was
also reproducible. The decrease in heart rate with NE
was -10.9 ± 1.8 bpm (first administration) and -8 .7
± 2.9 bpm (second administration), and -4 .9 ± 1.5
and —6.5 ± 1 . 1 bpm with pitressin. The chronotropic
effect of All was also reproducible, the change in
heart rate being -2 .9 ± 1.8 and -1 .2 ± 1.5 bpm
respectively, although the chronotropic effect of All
was variable depending upon individuals in such a way
that the heart rate was increased in one, decreased in
three, and unchanged in the remaining subject.
Effect of Captopril on the Cardiohemodynamic Responses to
Norepinephrine, Angiotensin II, and Pitressin (Groups 4, S
and 6)
Captopril did not reduce MAP in normal men
(table 1). However, the dose-response curve for NE
after captopril was located on the right of the control
curve (fig. 2 center); the slopes of both curves were not
significantly different from each other. There was a
significant difference between the corrected means of
data on pressor responses to NE before and after
captopril (p < 0.005); in other words, captopril
TABLE 1. Basal Data in Ten Groups
Group
no.
1
2
3
4
5
6
7
8
9
10
No. of
subjects
5
5
5
7
6
5
5
5
5
5
Age
(yrs)
22.2 ±1.3
23.8 ± 3.4
22.4 ±1.3
25.7 ± 2.1
23.8 ±1.5
22.2 ±1.3
26.8 ± 2.9
28.2 ± 2.6
31.2 ± 1.5
23.8 ±1.5
Weight
(kg)
62.4 ± 2.1
67.2 ± 3.0
62.4 ± 2.1
62.5 ± 2.3
67.2 ± 3.0
62.4 ± 2.1
61.4 ± 2.3
62.8 ± 0.5
63.4 ± 2.1
67.2 ± 3.0
Basal MAP
(mm Hg)
Control
period
84.2 ± 2.3
83.9 ± 5.1
84.3 ± 1.3
85.9 ± 2.6
84.9 ± 2.9
84.7 ± 1.8
83.2 ± 2.2
86.5 ± 2.2
83.9 ± 5.0
82.1 ± 5.6
Second
period
81.6 ±2.6
84.8 ± 5.3
83.9 ± 1.3
83.9 ± 3.1
81.6 ± 3.3
90.2 ± 3.4
82.8 ± 2.6
88.6 ± 2.0
85.6 ± 5.2
80.1 ± 2.9
Basal heart rate
(beats/min)
Control
period
55.5 ± 3.5
62.3 ± 4.0
60.6 ± 2.4
65.5 ± 3.6
65.3 ± 4.3
57.6 ± 3.2
64.4 ± 3.0
64.8 ± 1.1
64.4 ± 3.6
63.9 ± 5.0
Second
period
54.4 ± 2.7
61.4 ±4.2
57.8 ± 2.2
64.8 ± 2.9
62.4 ± 2.7
60.0 ±1.5
54.7 ± 2.0
63.3 ±1.0
65.0 ± 3.6
64.0 ± 4.6
In Groups 1, 2, and 3, no pretreatment was carried out in the second period. In Groups 4, 5, 6, and 10,
captopril was given in the second period. In Groups 7 and 8, captopril and a subpressor dose of angiotensin
II were given in the second period. In Group 9, bradykinin was infused in the second period. In Group 10,
indomethacin was given in the control and the second periods.
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FIGURE 1. Pressor responses to norepinephrine (upper),
angiotensin II (center), and pitressin (lower). Dotted
columns represent the period of infusion of vasopressor sub-
stances. MAP = mean arterial pressure.
significantly attenuated the pressor response to NE.
The control dose-response curves in Groups 1,4, and 7
were not significantly different from each other. The
dose-response curve after captopril in Group 4 was
significantly different from the control curves in
Groups 1 and 7 (p < 0.01).
Contrariwise, captopril slightly but significantly (p
< 0.01) potentiated the pressor response to All , as
shown in figure 3 right. The control dose-response
curves in Groups 2 and 5 were significantly different
from each other. The dose response curve after capto-
pril in Group 5 was significantly different from the
control curve in Group 2.
As shown in figure 4 center, captopril significantly
attenuated the pressor response to pitressin (p < 0.01).
The control pressor responses to pitressin in Groups 3,
6, and 8 were not significantly different from each
other. The pressor responses in control in Groups 3,6,
and 8 were pooled and compared with that after cap-
topril in Group 6. There was significant difference
between these responses {p < 0.02).
Although the increases in blood pressure caused by
NE and pitressin were significantly attenuated by cap-
topril, the decreases in heart rate caused by these
pressor substances after captopril were similar to
those before captopril. With NE, the decrease in heart
rate was -11.0 ± 1.2 bpm before and -11.4 ± 1.5
bpm after captopril. With pitressin, the decrease in
heart rate was -4 .0 ± 1.4 bpm before and -5 .5 ±1 .1
bpm after captopril. The change in heart rate caused
by All after captopril (-5.2 ± 2.4 bpm) was almost
similar to that before (-4.6 ± 3.3 bpm).
Effect of Captopril on the Cardiohemodynamic Responses to
Norepinephrine and Pitressin during Infusion of
Subdepressor Dose of Angiotensin II (Groups 7 and 8)
Infusion of All in a dose of 1 ng/kg min'1 in addi-
tion to captopril caused no significant change in MAP
or heart rate (table 1). With the infusion of All, the
attenuation by captopril of the pressor responses to
NE (fig. 2 right) and pitressin (fig. 4 right) dis-
appeared.
The changes in heart rate caused by NE (-8.8 ± 1.3
bpm) and pitressin (-4.5 ± 1.3 bpm) during combined
treatment with captopril and All were not sig-
nificantly different from those in the control period
(-10.1 ± 1.7 bpm and -2.9 ± 0.8 bpm respectively).
Effect of Infusion of a Subdepressor Dose of Bradykinin on
the Cardiohemodynamic Responses to Norepinephrine
(Group 9)
Infusion of BK in a dose of 0.1 /*g/kg min1 did not
decrease the MAP (table 1). In three of the five sub-
jects, BK infusion in a dose of 0.1 fig/kg min1 caused
a slight tachycardia and burning sensation. The
pressor response to NE during BK infusion (14.1 ±
4.7 mm Hg) was almost identical to the control
pressor response (15.0 ± 2.8 mm Hg). The brady-
cardia caused by NE was significantly less during BK
infusion (-3.3 ± 0.8 bpm) than in the control (-6.8 ±
1.0 bpm, p < 0.05).
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FIGURE 2. Reproducibility of the pressor response to norepinephrine (left), modification of the pressor
response to norepinephrine by captopril (center), and the effect of combined treatment with captopril and a
subdepressor dose of angiotensin II on the pressor response to norepinephrine (right). • — • control pres-
sor response; i—i pressor response to the second administration (left graph); A—A pressor response after
captopril (center); •—a pressor response during combined treatment (right). AMAP = change in mean
arterial pressure. **Significant difference from control dose-response curve (p < 0.01).
dMAP (mmHg)
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FIGURE 3. Reproducibility of the pressor response to
angiotensin II (left), and modification of the pressor
response to angiotensin II by captopril (right). • — • con-
trol pressor response; i—t pressor response to the second ad-
ministration (left); A—A pressor response after captopril
(right). Otherwise the same as figure 2.
4MAP (mmHg)
15
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*
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FIGURE 4. Reproducibility of the pressor response to
pitressin (left), modification of the pressor response by cap-
topril (center), and the effect of combined treatment with
captopril and a subdepressor dose of angiotensin II (right).
**Significant difference from control (p < 0.01). • control
pressor response; i pressor response to the second ad-
ministration (left); A pressor response after captopril
(center); o pressor response during combined treatment
(right). AMAP — change in mean arterial pressure.
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FIGURE 5. Effect of indomethacin on the pressor response
to norepinephrine (left), and the effect of combined treat-
ment with indomethacin and captopril on the pressor
response to norepinephrine (right). 1—1 control pressor
response obtained from 17 subjects who were not treated
with indomethacin (left); • — • pressor response obtained
from five subjects who were treated with indomethacin;
A ^ A pressor response during the combined treatment
(right). Otherwise the same as figure 2.
Effect of Captopril on the Cardiohemodynamic Responses to
Norepinephrine during Indomethacin Treatment (Group 10)
The pressor response to each dose of NE in the
group treated with indomethacin was not significantly
different from that of the group without indometh-
acin (fig. 5 left). However, as shown in figure 5 right,
the dose-response curves for NE was still attenuated
by captopril (p < 0.01) even in the presence of indo-
methacin. The reflex bradycardia during combined
treatment with captopril and indomethacin (-11.0 ±
2.5 bpm) was similar to that in the control (-10.8 ±
1.8 bpm).
Effect of Captopril on Plasma Renin Activity
The PRA recorded just prior to the second infusion
of NE (3.1 ± 0.9 ng/ml • 6 hrs"1, n = 5) was not
significantly different from that obtained just prior to
the first infusion of NE (3.0 ± 0.8 ng/ml • 6 hrs'1). The
PRA obtained 1 hour after captopril administration
and just prior to the infusion of NE (15.5 ± 5.2 ng/ml
• 6 hrs*1, n = 7) was significantly higher than that ob-
tained just prior to the infusion of NE in the control
period (3.8 ± 0.7 ng/ml • 6 hrs"1, p < 0.05).
Discussion
The influence of captopril on the pressor response to
NE has been investigated in animal experiments.
However, the results are conflicting. In vivo experi-
ments showed that captopril scarcely affected the
pressor response to NE in rabbits12 and rats.13
Recently, Spertini et al.14 reported that in normoten-
sive anesthetized rats acute converting enzyme
blockade by captopril did not blunt the pressor
response to NE and vasopressin, although chronic
blockade blunted the pressor response to NE. Rubin
et al.13 reported that captopril, in vitro, had little effect
on the contractile response of NE in the rat portal vein
and rabbit thoracic aorta, whereas some authors
reported that captopril attenuated the vasoconstrictor
effect of NE in the rat mesenteric artery9 or rat
isolated kidney.16 Our investigation presented here is
the first report that describes the effect of an angio-
tensin converting enzyme inhibitor on the responses to
exogenous vasopressor substances in humans. In the
present study, captopril, 50 mg by mouth, attenuated
the pressor responses to NE and pitressin in normal
human subjects. The question arises as to what
mechanism is involved for the attenuation of pressor
responses to vasopressor substances. Since captopril
attenuated the pressor responses to two vasopressor
substances (NE and pitressin), it is unlikely that the
attenuation was brought about by some specific
mechanisms such as adrenergic alpha-receptor
blockade. Since Al converting enzyme and kininase II
are the same enzyme,6 captopril potentiates a vaso-
depressor or a vasodilator action of BK. Thus, it is
possible that the attenuation of the pressor responses
to NE and pitressin might be due to counteraction of
endogenous BK. However, the pressor response to NE
was not attenuated by a subdepressor dose of BK,
even though this dose was sufficient to cause symp-
toms such as slight tachycardia and/or a burning sen-
sation.18 Therefore, it is unlikely that the attenuation
of pressor responses to the two vasopressors by cap-
topril was caused by an accumulation of BK.
Bradykinin is well known to promote the synthesis
of prostaglandins.17-18 It is proposed that a decrease in
blood pressure after captopril treatment in the rat was
the result of vasodilation produced through the in-
teraction of angiotensin-bradykinin-prostaglandin
system.19 Recently, some authors have suggested that
the potentiation of the prostaglandin system may con-
tribute to the antihypertensive action of captopril.7'20
Therefore, it is also possible that a prostaglandin
system activated by increased BK might attenuate
the pressor responses. However, attenuation of the
pressor response to NE by captopril also occurred
during indomethacin treatment. Therefore, it is un-
likely that a bradykinin-prostaglandin system might
contribute to the attenuation. The present results do
not completely rule out the contribution of an en-
dogenous bradykinin-prostaglandin system to the
effect of captopril, since the dose of indomethacin used
in the present study may not be enough to inhibit com-
pletely the prostaglandin synthesis.21
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The attenuation of pressor responses to NE and
pitressin does not depend on the specific change in the
arteriole by captopril, since it did not occur with the
other pressor agent, AIL In the present study, the
attenuation of the pressor responses to NE and pitres-
sin by captopril was abolished by infusion of a sub-
depressor dose of All . This suggests that the depletion
of endogenous All by captopril may have some rela-
tionship to the attenuation of the pressor responses
to vasopressor substances. Recently, Moulds and
Worland22 reported that All potentiated vaso-
constrictor effects of NE, KC1, BaCl2, and 5-HT in
human vasculature. Thoenen et al.28 reported that All
enhanced excitation-contraction coupling of vascular
smooth muscle. Day and Moore" provided evidence
that All may potentiate the effects of NE and other
vasopressor substances by inhibiting the active extru-
sion of sodium from the vascular smooth muscle cells,
thereby causing a nonspecific sensitization. If so, de-
pletion of endogenous All by captopril may lead to
the diminution of pressor responses to vasopressor
substances. The attenuation of the pressor responses
to NE and vasopressin by captopril observed in the
present study could be an expression of the loss of the
sensitizing effect of endogenous All .
In our present study, the pressor response to All
was potentiated after captopril. It is reported that the
nonapeptide teprotide28' *• and captopril71 27> M poten-
tiate the pressor response to exogenous All . Thurston
and Laragh26 postulated that the potentiation of the
pressor response to exogenous All observed during
converting enzyme inhibition results from decreased
competition for receptor sites to endogenous All and
increased availability of vascular receptor site to
exogenous AIL
Reflex compensation mediated through the baro-
receptors to acute elevation of arterial pressure could
be an important contributor to the homeostasis of
blood pressure. In the present study, the decrease in
heart rate in response to NE and pitressin after capto-
pril was almost similar to that in control, while the
pressor responses to both vasopressor substances were
lower with captopril than in control, indicating that
reflex slowing of the heart was potentiated by capto-
pril. This potentiation would be due to depletion
of endogenous All , since the potentiation of reflex
bradycardia disappeared during infusion of AIL
Conversely, the attenuation of the pressor response to
NE also disappeared during infusion of AIL Thus, it
is likely that potentiation of baroreflex mechanism by
captopril may lead to the attenuation of pressor
responses to vasopressor substances. It is known that
angiotensin has access to the central nervous system at
sites where the blood-brain barrier is deficient, such as
the area postrema. Joy and Lowe29 reported that a
centrally mediated cardiovascular effect elicited by
vertebral artery infusion of All is suppression of car-
diac vagal tone. Recently, Lee et al.80 demonstrated
that All showed a dose-dependent positive chrono-
tropic action through dose-dependent reduction in
vagal tone but not through activation of the central
and peripheral sympathetic system. Recently, we
reported that captopril caused instantaneous drop of
blood pressure without compensatory tachycardia or
with a mild degree of bradycardia. Hypotensive and
chronotropic effects of captopril were almost the same
in untreated and treated patients with sympatholytic
and/or adrenergic /3-receptor blocking agents. Fur-
thermore, we observed a significant negative correla-
tion between the change in heart rate and PRA ob-
tained immediately before captopril administration.81
The present study and some other studies cited here
might suggest that depletion of endogenous All by
captopril might cause potentiation of reflex slowing of
the heart in response to vasopressor substances
through potentiation of centrally mediated vagal tone.
In our present study, the initial increase in blood
pressure was unsustained and returned to the basal
level during pitressin infusion; this unsustained initial
increase after a high dose of pitressin or vasopressin
has also been observed by several authors.82"34 As
a possible mechanism, Montani et al.85 recently
suggested that vasopressin induces the reduction of
cardiac output is through a cardiovascular reflex. Dur-
ing pitressin or vasopressin infusion, the rising plas-
ma vasopressin concentrations specifically increase
the feedback gain of the cardiovascular reflex system,
so that the vasopressor effect of vasopressin will be
buffered more than that of other pressor agents.
Finally, we should justify the dose of captopril used
in the present study. In our previous study, we found
that in hypertensive patients captopril (50 mg by
mouth) caused a significant decrease in MAP, which
reached a maximum level at 1 hour after administra-
tion and stayed at that level for 1 hour.88-87 Further-
more, Ferguson et al.8 reported that oral administra-
tion of 20 mg of captopril completely inhibited the
pressor response to 10 ng/kg of Al for 2.5 hours
in human subjects. Therefore, the dose of captopril,
50 mg by mouth, used in the present study could be
sufficient to block angiotensin converting enzyme. In
our present study, we measured neither the plasma
level of All nor the effect of AL After captopril treat-
ment, however, the PRA was clearly increased. This
reflects the blocking of the negative short-feedback
mechanism of All by angiotensin converting enzyme
inhibitor.2'88
In conclusion, the attenuation of pressor responses
by captopril may be explained by its inhibition of
angiotensin formation; decreased All may desensitize
the contraction of arterial smooth muscle and may
potentiate the compensatory reflex mechanism.
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